FULGENT GENETICS, INC. Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross
FULGENT GENETICS, INC. (FLGT) had Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross of $21.00 thousand as of 2018-12-31, per its 10-K filed 2020-03-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross · last filed 2020-03-13
- 2018-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $21.00K.
- 2017-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $37.00K.
- 2016-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $58.00K.
| Period end | Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross |
|---|---|
| 2018-12-31 | $21.00K 10-K · filed 2020-03-13 |
| 2017-12-31 | $37.00K 10-K · filed 2019-03-22 |
| 2016-12-31 | $58.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |